Shanghai Junshi Biosciences Co.Ltd(688180) : we will communicate with the regulatory authorities and submit covid-19 oral drug listing application in the near future

On May 23, Shanghai Junshi Biosciences Co.Ltd(688180) announced that, The product of oral nucleoside anti SARS cov-2 drug vv116 tablets (project code: jt001/vv116, referred to as “vv116”) jointly developed by the holding subsidiary Shanghai juntuo Biomedical Technology Co., Ltd. and Suzhou Wangshan wangshui biomedical Co., Ltd. is in a phase III registered clinical study (nct05341609) on the early treatment of mild to moderate novel coronavirus pneumonia (“covid-19”) with binemavir tablets / ritonavir tablets (paxlovid) Reach the primary end point preset by the scheme. The company will communicate with the regulatory authorities on the submission of new drug listing applications in the near future.